Sentry Investment Management LLC Sells 557 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sentry Investment Management LLC trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 23.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,866 shares of the medical equipment provider's stock after selling 557 shares during the quarter. Intuitive Surgical comprises about 0.5% of Sentry Investment Management LLC's holdings, making the stock its 28th largest position. Sentry Investment Management LLC's holdings in Intuitive Surgical were worth $865,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. RFG Advisory LLC grew its position in Intuitive Surgical by 309.4% during the first quarter. RFG Advisory LLC now owns 3,238 shares of the medical equipment provider's stock worth $1,604,000 after buying an additional 2,447 shares in the last quarter. Capital Asset Advisory Services LLC boosted its holdings in shares of Intuitive Surgical by 6.3% in the 1st quarter. Capital Asset Advisory Services LLC now owns 6,807 shares of the medical equipment provider's stock worth $3,451,000 after purchasing an additional 401 shares in the last quarter. Fulton Bank N.A. boosted its holdings in shares of Intuitive Surgical by 0.6% in the 1st quarter. Fulton Bank N.A. now owns 3,802 shares of the medical equipment provider's stock worth $1,883,000 after purchasing an additional 24 shares in the last quarter. HBW Advisory Services LLC boosted its holdings in shares of Intuitive Surgical by 11.1% in the 1st quarter. HBW Advisory Services LLC now owns 542 shares of the medical equipment provider's stock worth $268,000 after purchasing an additional 54 shares in the last quarter. Finally, ST Germain D J Co. Inc. boosted its holdings in shares of Intuitive Surgical by 69.8% in the 1st quarter. ST Germain D J Co. Inc. now owns 73 shares of the medical equipment provider's stock worth $36,000 after purchasing an additional 30 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Robert W. Baird cut their price objective on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Evercore ISI cut their price objective on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a report on Wednesday, April 23rd. Barclays cut their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. BTIG Research set a $560.00 price objective on Intuitive Surgical and gave the stock a "buy" rating in a report on Monday, April 14th. Finally, Citigroup restated a "buy" rating and set a $650.00 target price (up from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $596.05.

Insider Activity

In other Intuitive Surgical news, EVP Robert Desantis sold 11,545 shares of Intuitive Surgical stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $499.22, for a total value of $5,763,494.90. Following the completion of the sale, the executive vice president now owns 5,224 shares of the company's stock, valued at approximately $2,607,925.28. This trade represents a 68.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jami K. Nachtsheim sold 2,400 shares of Intuitive Surgical stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the sale, the director now directly owns 6,371 shares of the company's stock, valued at approximately $3,312,920. The trade was a 27.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,286 shares of company stock worth $12,594,546 over the last 90 days. 0.70% of the stock is currently owned by insiders.

Intuitive Surgical Stock Up 1.1%

Shares of NASDAQ:ISRG traded up $6.10 during trading on Wednesday, hitting $557.95. The stock had a trading volume of 1,146,710 shares, compared to its average volume of 1,645,424. Intuitive Surgical, Inc. has a 12 month low of $397.47 and a 12 month high of $616.00. The company has a market capitalization of $199.98 billion, a PE ratio of 87.04, a PEG ratio of 5.85 and a beta of 1.67. The firm's fifty day moving average is $518.20 and its 200 day moving average is $538.82.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The firm had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same period last year, the company earned $1.50 earnings per share. Equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.